Interview Questions78

    When Portfolio Companies Struggle: Sponsors in Distress

    How sponsors choose between new equity, lender deals, liability management and handing over the keys, and where the bank sits when a portfolio company fails.

    |
    8 min read
    |
    2 interview questions
    |
    Share

    Introduction

    A sponsor whose portfolio company can no longer carry its debt always has one option that costs nothing more: giving the company to its lenders. Every other route, from an equity cure to new money, an amendment or a liability management transaction (LMT), has to beat that baseline, because each spends fund capital, lender goodwill or time on a stake the market may value at zero. KKR took both kinds of route at Marelli, the auto parts supplier it assembled in 2019: new equity in 2022, a handover to lenders in 2025. The bank's part is complicated because it may sit on several sides at once, as lender, agent, hedge counterparty and adviser, while its financial sponsors group (FSG) relationship with the client has to survive the loss.

    Five Ways a Sponsor Can Respond to Distress

    Trouble shows first as shrinking covenant headroom and falling loan marks, signals monitoring between portfolio reviews exists to catch, then as a test the company will fail or a maturity no lender will refinance. The sponsor's options, ordered roughly by how much of its own capital each spends:

    RouteWhat the sponsor puts inWhat it keepsWho else must agree
    Equity cure or new equityFund capitalControl and the full upsideNone for a cure; lenders if new securities rank ahead
    Amendment or amend-and-extendFees, a higher margin, often equityControl, under tighter termsLenders, under the voting rules
    Liability management transactionLittle or no equityControl, at a cost in goodwillThe lender majority the documents require
    Sale under stressTime and a lower priceAny value above the debt, often noneLenders, if proceeds fall short
    Handing over the keysNothing moreReleases, sometimes a small stakeThe secured lenders

    An equity cure, introduced with the covenants in the buyout financing article's covenant section, lets the sponsor's cash count toward one test, within caps set out in the restructuring guide's treatment of covenant breaches. A cure buys time, not a solution, so a sponsor that has cured twice is usually deciding whether to write a larger check as new common or preferred equity.

    Amendments, Forbearance and Liability Management

    Lenders will waive or reset a test for a fee and a wider margin, and a forbearance agreement can hold off enforcement while terms are agreed. An extension sought under stress differs from amend-and-extend as a routine hold-period tool: lenders asked to carry a weak credit longer typically want the sponsor to share the risk with new equity.

    An LMT keeps the equity alive with other people's money, using room in the documents to raise debt or extend maturities with a majority of lenders, often at the expense of the rest; why liability management transactions took over is restructuring material. The sponsor's price is lender goodwill, owed to funds and banks that finance its other companies.

    Consensual Foreclosure (Handing Over the Keys)

    A transfer of a company's ownership to its lenders with the existing owner's agreement, typically by converting debt into equity out of court or under a prearranged bankruptcy plan rather than through contested enforcement. The sponsor's shares are cancelled or transferred, usually in exchange for releases and occasionally a small residual stake.

    A handover is not a failed business. The company usually keeps operating with less debt and new owners; what the sponsor declines is the price of remaining the owner.

    What Drives the Sponsor's Decision

    The same company can justify sponsor support from one owner and a handover from another, because the decision turns on the sponsor's own position as much as on the business.

    The Option Value of Equity Below Water

    Equity in a company worth less than its debt would receive nothing in a sale today, yet it keeps an option on recovery while the company avoids a default that hands control to creditors. New money buys time, and time is what an option is worth, which is why lenders ask the sponsor to pay for an extension with equity rather than fees alone.

    One such check paid off: Blackstone's second equity injection into Hilton in 2010 bought back mezzanine debt below half its face value, a turn the Hilton buyout case study follows to a gain of about $14 billion.

    Fund Age, Reserves and Cross-Holdings

    A fund still investing usually holds reserves for follow-on investments; a fund near the end of its term may have little uncalled capital, and a check from a newer fund into an older fund's company sets one group of limited partners (LPs) against another, a conflict that commonly needs approval from the LP advisory committee. Some sponsors borrow against the fund's portfolio instead, one of the fund-level tools.

    Cross-Holding (Private Equity)

    A position in which one sponsor's funds hold more than one layer of the same company's capital, such as a buyout fund owning the equity while the firm's credit funds hold its loans. In distress the layers' interests diverge, so each fund's duty to its own investors must be managed separately.

    A cross-holding can ease a consensual deal, because the firm sits on both sides, or slow it, because every vote must be handled fund by fund.

    Reputation With Lenders and Limited Partners

    Sponsors borrow from the same direct lenders and banks across dozens of companies, so an aggressive LMT that saves one company's equity can raise the price of the next financing, while a record of support makes lenders readier to extend. Declining to fund is legitimate too: Thoma Bravo's refusal to put more into Medallia left its lenders as owners, as the article on credit managers that become owners describes. LP optics cut both ways: a write-off shows before the next fundraise, and so does a lost rescue check.

    Marelli: KKR's Two Decisions at One Company

    KKR built Marelli in May 2019, when Calsonic Kansei, the Japanese supplier it already owned, completed its purchase of Magneti Marelli from Fiat Chrysler Automobiles.

    2022: New Equity for a Debt Cut

    Marelli opened a Japanese alternative dispute resolution (ADR) workout on March 1, 2022. When some lenders withheld approval on June 24, the ADR closed and the company filed for rehabilitation at the Tokyo District Court, as Mizuho's disclosure of its exposure records. On July 19, lenders holding more than 90% of the bank debt approved a plan built on new equity capital from KKR and a reduction of existing bank debt, and the court confirmed it. Bloomberg reported that the plan sought to cancel about ¥450 billion of roughly ¥1.13 trillion of debt: the support route, with KKR keeping control and the banks writing down their loans.

    2025: The Lenders Take the Company

    On June 11, 2025, Marelli filed for Chapter 11 in Delaware with a restructuring support agreement signed by about 80% of its lenders, KKR also a party as equity sponsor. The company's announcement set out $1.1 billion of debtor-in-possession (DIP) financing and the elimination of all secured debt, with the DIP lenders taking ownership unless a 45-day overbid process produced a better offer. PJT Partners advised the company; the ad hoc lender group retained Houlihan Lokey.

    No superior offer arrived, and in late July 2025 the company said it expected to emerge in 2026 owned by its principal lenders: Deutsche Bank, Strategic Value Partners, MBK Partners, Fortress Investment Group and Polus Capital Management. Why a prearranged filing beat another workout is a choice the restructuring guide analyses. The filings do not give KKR's reasons, but they fit the drivers above: a first check bought time, and a second would have bought a smaller option on a larger gap.

    Where the Bank Stands When a Sponsor's Company Struggles

    A bank close to a sponsor rarely meets its distressed company as a stranger. It may be agent on the buyout loan, a revolver lender and the company's interest rate hedge counterparty, while its coverage team serves the sponsor across the portfolio.

    Lender, Agent and Adviser at Once

    Distress puts those seats in conflict. A bank that lends to the company generally cannot advise it on a restructuring that would impair its own loan, which is why restructuring advice clusters at firms without balance-sheet conflicts. The usual line-up mirrors Marelli's: an independent restructuring adviser for the company, an ad hoc lender group with its own banker, and the bank's loan run by its credit or workout staff. The sponsor often takes separate counsel.

    The coverage work shifts to coordination: telling the sponsor who at the bank speaks for each seat, bringing in restructuring colleagues where the bank is not conflicted, and keeping the sponsor's other companies moving.

    Keeping the Relationship Through a Loss

    A failed investment ends one company's story, not the account. The sponsor still owns other companies and raises the next fund, and it remembers which banks stated their positions plainly. Sponsors and lenders are repeat players.

    So the cheapest option has a price after all. Handing over the keys costs no new money, but every lender watches how it is managed and will be asked to finance something else for the same client. A sponsor whose next loan is priced as though nothing happened, by banks that sat across the table, has kept what matters most for its next deal: access to credit after a loss.

    Interview Questions

    2
    Question #1Medium

    A credit agreement caps leverage at 5.0x. The company has $440 million of debt and $80 million of LTM EBITDA. How much equity does the sponsor need to cure the breach if the cure must repay debt, and how much if the agreement lets the cure count as EBITDA?

    Today the company is at 5.5x ($440 million / $80 million). To get back to 5.0x:

    • •If the cure repays debt: debt must fall to 5.0 x $80 million = $400 million, so the sponsor injects $40 million.
    • •If the cure counts as EBITDA: EBITDA must rise to $440 million / 5.0 = $88 million, so the sponsor injects only $8 million.

    The difference is large because an EBITDA cure is multiplied by the leverage ratio: each dollar of equity counts as a dollar of earnings, which supports five dollars of debt at a 5.0x test. A cure that repays debt only removes debt dollar for dollar.

    That is why lenders limit EBITDA cures. Agreements usually cap how often a cure can be used (for example, not in consecutive quarters and only a few times over the life of the loan), cap the amount, and often say the cure counts only for the covenant test, not for other baskets or pricing. A cure also only buys time: the amount stays in the trailing EBITDA for the next few tests, but it is sized for today's shortfall, so if earnings keep falling the company breaches again, and the number of cures is capped. If the business keeps weakening, the sponsor faces the bigger decision of whether to put in real new equity or negotiate with its lenders.

    Rate yourself:
    Question #2Hard

    A portfolio company is about to breach its leverage covenant. What are the sponsor's options, and how does it decide whether to put in more money?

    The sponsor's options range from spending more of its own money to spending none:

    1. 1.Equity cure: inject equity that counts toward the covenant test, within the caps in the documents. This buys time, not a solution.
    2. 2.New equity: a larger check, as common or preferred equity, to pay down debt and fund the plan.
    3. 3.Amendment or waiver: lenders reset or waive the test in exchange for fees, a higher margin and often new sponsor equity. An amend-and-extend can also push out maturities.
    4. 4.Liability management transaction: using room in the documents to raise new debt or extend maturities with a majority of lenders, often at the expense of the others. It keeps the equity alive but costs goodwill with lenders the sponsor will need again.
    5. 5.A sale under stress, or handing the company to its lenders, usually in exchange for releases.

    The decision turns on a few questions:

    • •Whether the equity is worth backing: equity in a company worth less than its debt still has option value if the business can recover. New money buys time, so it makes sense only if the sponsor genuinely believes in the recovery case.
    • •What the fund can afford: A fund near the end of its life may have little reserve capital left, and putting a newer fund's money into an older fund's company creates a conflict between two groups of LPs.
    • •Relationships: sponsors borrow from the same lenders across many companies, so an aggressive tactic can raise the cost of every future financing, while a record of support makes lenders more willing to help.

    Handing over the keys does not mean the business has failed: it usually keeps operating with less debt. The sponsor has decided that staying the owner is no longer worth the price.

    Rate yourself:

    Explore More

    Investment Banking in Hong Kong and Singapore

    Investment banking in Hong Kong and Singapore: how the two hubs split Asia, Mandarin rules, APAC recruiting dates, visas, and analyst pay in HKD and SGD.

    August 27, 2026

    How to Value a Bank: FIG Valuation Explained

    How to value a bank when EV/EBITDA breaks down: master P/TBV, ROE, the justified P/B formula, and the dividend discount model for FIG interviews.

    July 20, 2026

    Buybacks vs Dividends: How Companies Return Cash

    Buybacks vs dividends explained: how each returns cash to shareholders, the tax and signaling differences, the EPS effect, and when each makes sense.

    June 25, 2026

    Ready to Transform Your Interview Prep?

    Join 5,000+ students preparing smarter

    Join 10,000+ students who have downloaded this resource